Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024

Moomoo 24/7Apr 18 07:02 ET

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Revive Therapeutics Ltd. (RVV.CN) on Tuesday provided an update on its clinical study evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder

MT NewswiresApr 2 08:31 ET

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillami...

Stockhouse Mar 27 09:08 ET

Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID

Stockhouse Mar 19 07:00 ET

Revive Therapeutics Provides Corporate Update

Stockhouse Mar 12 07:00 ET

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

Stockhouse Feb 1 07:30 ET